Darius Babusis

机构：Gilead Sciences (United States) · ORCID：0000-0001-5599-1671

发表论文 81 篇 · 总被引 8450 次 · h-index 31

代表论文

• Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets (2021 · Nature Communications · 被引 131)
• Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice (2022 · Science Translational Medicine · 被引 83)
• Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (2023 · Journal of Medicinal Chemistry · 被引 63)
• Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus (2024 · Science · 被引 42)
• Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection (2021 · Science Translational Medicine · 被引 42)
• Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates (2025 · Nature Medicine · 被引 28)